Shots:
NICE has recommended Hansa’ Idefirix as a clinically and cost-effective treatment to enable transplantation for highly sensitized kidney transplant patients in England, Wales, and Northern Ireland before kidney transplant from a deceased donor
Hansa will collaborate with national health service commissioners to support the service’s implementation, following NICE recommendations
Imlifidase has the potential to specifically target & cleave all classes of IgG Abs & is being evaluated in the 4 P-II trials to evaluate the efficacy and safety as a pre-transplant treatment to reduce donor-specific IgG. The therapy has also received marketing authorization in the EU in Aug 2020
Ref: PR Newswire | Image: Hansa
